Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats
Authors:
- 1 June 2011
- journal article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 34 (6) , 941-948
Abstract
The aim of the present study was to investigate the effect of liposome-encapsulation and liposome-size on the in vivo pharmacokinetics of interferon α-2b (IFNα-2b) following i.m. administration to rats, and whether there was any liver-targeting of these liposomes. Since liposomes of different sizes can be obtained by homogenization, the effect of homogenization on the IFNα-2b activity was also investigated. The pharmacokinetics of IFNα-2b solution (12.8 μg/kg) and IFNα-2b prepared in liposomes, including three mean sizes of 172 nm (12.2μg/kg), 113 nm (44.2, 11.0, and 2.8μg/kg, respectively), and 82 nm (13.1 μg/kg), were studied after a single i.m. dose to rats. Compared to a solution of IFNα-2b. administration of liposomal IFNα-2b resulted in a significantly prolonged tmax, the apparent elimination half life (t1/2β) was 2.3 times longer, both AUC0-∞ and MRT0-∞ were also clearly enhanced and greater accumulation was obtained in the liver (p < 0.05). The AUC0-∞ increased proportionally to the administered dose of IFNα-2b liposomes. Moreover, the size of liposomes ranging from 82 nm to 172 nm had no significant difference on the pharmacokinetic behavior in vivo (p > 0.05). In sum, compared with the free form, IFNα-2b encapsulated in liposomes can alter strikingly the pharmacokinetics properties following i.m. injection and if a liposomal size ranging from 82 nm to 172 nm was used, consistent pharmacokinetic behaviors of IFNα-2b was exhibited. The liposomal formulation apparently targeted the liver, offering a potential advantage for hepatitis B treatment.Keywords
This publication has 20 references indexed in Scilit:
- A novel method to prepare highly encapsulated interferon-α-2b containing liposomes for intramuscular sustained releaseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2006
- Treatment of hepatitis BJournal of Gastroenterology, 2002
- Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspectsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2001
- Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.Biochimica et Biophysica Acta (BBA) - Biomembranes, 1997
- Modulation of pharmacokinetic behavior of liposomesAdvanced Drug Delivery Reviews, 1997
- Preparation and characterization of interferon-γ-containing liposomesInternational Journal of Pharmaceutics, 1995
- Influence of Size of Liposomes in Potentiating the Efficacy of Encapsulated Triethylenetetramine-hexaacetic Acid(TTHA) Against Cadmium Intoxication.Industrial Health, 1993
- Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1992
- Use of 125 I-Interferons in Pharmacokinetic and Tissue Distribution StudiesJournal of Interferon Research, 1984
- Fate of cholesterol-rich liposomes after subcutaneous injection into ratsBiochimica et Biophysica Acta (BBA) - General Subjects, 1983